Vivos Therapeutics Inc (VVOS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Vivos Therapeutics Inc stock (VVOS) is currently trading at $1.14. Vivos Therapeutics Inc PS ratio (Price-to-Sales) is 0.76. Analyst consensus price target for VVOS is $5.00. WallStSmart rates VVOS as Sell.
- VVOS PE ratio analysis and historical PE chart
- VVOS PS ratio (Price-to-Sales) history and trend
- VVOS intrinsic value — DCF, Graham Number, EPV models
- VVOS stock price prediction 2025 2026 2027 2028 2029 2030
- VVOS fair value vs current price
- VVOS insider transactions and insider buying
- Is VVOS undervalued or overvalued?
- Vivos Therapeutics Inc financial analysis — revenue, earnings, cash flow
- VVOS Piotroski F-Score and Altman Z-Score
- VVOS analyst price target and Smart Rating
Vivos Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Vivos Therapeutics Inc (VVOS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Vivos Therapeutics Inc (VVOS) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Revenue surging 75.70% year-over-year
Supporting Valuation Data
Vivos Therapeutics Inc (VVOS) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 5.0x book value
Very low institutional interest at 11.03%
Micro-cap company with very limited liquidity and high volatility
Vivos Therapeutics Inc (VVOS) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Revenue Growth. Valuation metrics including Price/Sales (0.76) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 75.70%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (5.00) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -335.40%, Operating Margin at -69.80%, Profit Margin at -98.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -335.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 75.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VVOS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VVOS's Price-to-Sales ratio of 0.76x trades at a deep discount to its historical average of 2.26x (17th percentile). The current valuation is 91% below its historical high of 8.87x set in Dec 2023, and 441% above its historical low of 0.14x in Sep 2023. Over the past 12 months, the PS ratio has compressed from ~2.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Vivos Therapeutics Inc (VVOS) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Vivos Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 17M with 76% growth year-over-year. The company is currently unprofitable, posting a -98.8% profit margin.
Key Findings
Revenue growing at 76% YoY, reaching 17M. This pace significantly outperforms most MEDICAL DEVICES peers.
The company is unprofitable with a -98.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Vivos Therapeutics Inc maintain 76%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 7.02, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Vivos Therapeutics Inc.
Bottom Line
Vivos Therapeutics Inc is a high-conviction growth story with revenue accelerating at 76% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -98.8% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 8:23:21 AM
About Vivos Therapeutics Inc(VVOS)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Vivos Therapeutics, Inc., a medical technology company, is dedicated to developing and commercializing treatment alternatives for patients with sleep-disordered breathing, such as mild to moderate obstructive sleep apnea (OSA). The company is headquartered in Highlands Ranch, Colorado.